| Date | Time | Source | Headline | Symbol | Company |
| 02/06/2014 | 8:00AM | Business Wire | Enanta Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference Presentation to be Webcast on February 13,... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/04/2014 | 6:03AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/03/2014 | 4:10PM | Business Wire | Enanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy & ... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/03/2014 | 9:46AM | Zacks | Enanta (ENTA) Worth Watching: Stock Rises 13.4% - Tale of the Tape | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/31/2014 | 7:56AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/31/2014 | 7:44AM | Business Wire | Enanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/13/2014 | 7:30AM | Business Wire | Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 01/06/2014 | 8:30AM | Business Wire | Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 12/26/2013 | 5:00PM | Zacks | Sucampo Reports Data - Analyst Blog | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 12/10/2013 | 8:02AM | Business Wire | Enanta Pharmaceuticals Announces 96 Percent SVR12 in Treatment Experienced Genotype 1 Hepatitis C Patients in SAPPHIRE-II Study | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/25/2013 | 4:05PM | Business Wire | Enanta Pharmaceuticals to Present at the Deutsche Bank 2013 BioFest | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/25/2013 | 7:30AM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for the Fiscal Fourth Quarter and Year Ended September 30, 2013 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/25/2013 | 7:00AM | Business Wire | Enanta Pharmaceuticals Announces the Appointment of Bruce L.A. Carter, Ph.D. to Board of Directors | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/19/2013 | 12:33PM | Zacks | Prescription for Profit - Zacks Industry Rank Analysis | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/19/2013 | 12:33PM | Zacks | Prescription for Profit - Zacks Industry Rank Analysis | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/18/2013 | 8:02AM | Business Wire | Enanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I Study | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/18/2013 | 8:00AM | PR Newswire (US) | AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Pe... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/18/2013 | 8:00AM | PR Newswire (US) | AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Pe... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2013 | 8:39AM | Dow Jones News | Kingdon Capital Management 3Q 13F: Holdings As Of -2- | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2013 | 8:39AM | Dow Jones News | Kingdon Capital Management 3Q 13F: Holdings As Of Sep 30 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2013 | 8:30AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter & Year Ended Septem... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2013 | 6:39AM | Dow Jones News | CR Intrinsic Investors 3Q 13F: Largest Purchases | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/15/2013 | 6:39AM | Dow Jones News | CR Intrinsic Investors 3Q 13F: Largest Purchases -2- | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/06/2013 | 4:30PM | Business Wire | Enanta Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/03/2013 | 9:00AM | Business Wire | New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/11/2013 | 6:17PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/02/2013 | 6:32PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/01/2013 | 10:15AM | Business Wire | Enanta Announces New Data on ABT-450 Regimens to be Presented at The Liver Meeting (AASLD) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/03/2013 | 8:14AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/03/2013 | 8:00AM | Business Wire | Enanta Pharmaceuticals Announces National Institute of Allergy & Infectious Diseases (NIAID) Will Fund Further Development of... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |